Seminars in Hematology
Volume 43, Issue 2 , Pages 126-133 , April 2006

Management of Acute Lymphoblastic Leukemia in Older Patients

  • Richard A. Larson

      Affiliations

    • Corresponding Author InformationAddress correspondence to Richard A. Larson, MD, University of Chicago, MC-2115, 5841 S Maryland Ave, Chicago, IL 60637.

References 

  1. National Cancer Institute, Surveillance, Epidemiology, and End Results Program. www.seer.cancer.gov
  2. Thomas X , Olteanu N , Charrin C , Lheritier V , Magaud JP , Fiere D . Acute lymphoblastic leukemia in the elderly (The Edouard Herriot Hospital experience) . Am J Hematol . 2001;67:73–83
  3. Göbuget N , Hoelzer D , Arnold R , Bohme A , Bartram CR , Freund M , et al.   Subtypes and treatment outcome in adult acute lymphoblastic leukemia less than or greater than 55 years . Hematol J . 2001;1(suppl 1):186
  4. Robak T , Szmigielska-Kaplon A , Wrzesien-Kus A , Wierzbowska A , Skotnicki AB , Piatkowska-Jakubas B , et al.   Acute lymphoblastic leukemia in elderly (The Polish Adult Leukemia Group experience) . Ann Hematol . 2004;83:225–231
  5. Mrozek K , Heerema NA , Bloomfield CD . Cytogenetics in acute leukemia . Blood Rev . 2004;18:115–136
  6. Secker-Walker LM , Prentice HG , Durrant J , Richards S , Hall E , Harrison G  MRC Adult Leukaemia Working Party . Cytogenetics adds independent prognostic information in adults with acute lymphoblastic leukaemia on MRC trial UKALL XA . Br J Haematol . 1997;96:601–610
  7. Groupe Francais de Cytogenetique Hematologique . Cytogenetic abnormalities in adult acute lymphoblastic leukemia (Correlations with hematologic findings and outcome) . Blood . 1996;87:3135–3142
  8. Wetzler M , Dodge RK , Mrozek K , Carroll AJ , Tantravahi R , Block AW , et al.   Prospective karyotype analysis in adult acute lymphoblastic Leukemia. The Cancer and Leukemia Group B experience . Blood . 1999;93:3983–3993
  9. Appelbaum FR . Impact of age on the biology of acute leukemia . In:  Perry MC editors. American Society of Clinical Oncology Educational Book. . 2005;p. 528–532
  10. Secker-Walker LM , Clark R , Hawkins JM , Maritineau M , Moorman AV . Age distribution of good and poor risk chromosomal subgroups among the first 1500 cases in the LRF UKCCG karyotype database in acute lymphoblastic leukemia . Br J Haematol . 1997;97(suppl 1):45; (abstr)
  11. Kantarjian HM , O’Brien S , Smith TL , Cortes J , Giles FJ , Beran M , et al.   Results of treatment with hyper-CVAD, a dose-intensive regimen, for adult acute lymphoblastic leukemia . J Clin Oncol . 2000;18:547–561
  12. Lewis JH , Kilgore ML , Goldman DP , Trimble EL , Kaplan R , Montello MJ , et al.   Participation of patients 65 years of age or older in cancer clinical trials . J Clin Oncol . 2003;21:1383–1389
  13. Talarico L , Chen G , Pazdur R . Enrollment of elderly patients in clinical trials for cancer drug registration (A 7-year experience by the US Food and Drug Administration) . J Clin Oncol . 2004;22:4626–4631
  14. Chessels JM , Hall E , Prentice HG , Durrant J , Bailey CC , Richards SM . The impact of age on outcome in lymphoblastic leukaemia; MRC UKALL X and XA compared (A report from the MRC Paediatric and Adult Working Parties) . Leukemia . 1998;112:463–473
  15. Larson RA , Dodge RK , Burns CP , Lee EJ , Stone RM , Schulman P , et al.   A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia (Cancer and Leukemia Group B study 8811) . Blood . 1995;85:2025–2037
  16. Larson RA , Dodge RK , Linker CA , Stone RM , Powell BL , Lee EJ , et al.   A randomized controlled trial of filgrastim during remission induction and consolidation chemotherapy for adults with acute lymphoblastic leukemia (CALGB study 9111) . Blood . 1998;92:1556–1564
  17. Gökbuget N , de Wit M , Gerhardt A , Lipp T , Rieder H , Schwartz S , et al.   Results of a shortened, dose reduced treatment protocol in elderly patients with acute lymphoblastic leukemia . Blood . 2000;96(suppl 1):718a; (abstr 3104)
  18. Hoelzer D , Gökbuget N , Beck J , Burmeister T , Giagounidis A , Glasmacher A , et al.   Subtype adjusted therapy improves outcome of elderly patients with acute lymphoblastic leukemia . Blood . 2004;104(suppl 1): (abstr 2732)
  19. Hoelzer D , Gökbuget N . Treatment of elderly patients with acute lymphoblastic leukemia . In:  Perry MC editors. American Society of Clinical Oncology Educational Book. . 2005;p. 533–539
  20. Pagano L , Mele L , Trape G , Leone G . The treatment of acute lymphoblastic leukaemia in the elderly . Leuk Lymph . 2004;45:117–123
  21. Pagano L , Mele L , Casorelli I , Fianchi L , Di Febo A , Leone G . Acute lymphoblastic leukemia in the elderly. A twelve-year retrospective, single center study . Haematologica . 2000;85:1327–1329
  22. Taylor PRA , Reid MM , Proctor SJ . Acute lymphoblastic leukaemia in the elderly . Leuk Lymph . 1994;13:373–380
  23. Crome P . What’s different about older people? . Toxicology . 2003;192:49–54
  24. Bressler R , Bahl J . Principles of drug therapy for the elderly patient . Mayo Clin Proc . 2003;78:1564–1577
  25. Lipschitz DA . Age related decline in hematopoietic reserve capacity . Semin Oncol . 1995;22:3–5
  26. Ottmann OG , Wassmann B . Treatment of Philadelphia chromosome positive acute lymphoblastic leukemia, in Berliner N . In: Hematology 2005 . Washington, DC: American Society of Hematology; 2005;p. 118–122
  27. Gleissner B , Gokbughet N , Bartram CR , et al.   Leading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia (A prospective study of the German Multicenter Trial Group) . Blood . 2002;99:1536–1543
  28. Czuczman MS , Dodge RK , Stewart CC , Frankel SR , Davey FR , Powell BL , et al.   Value of immunophenotyping in intensively treated adult acute lymphoblastic leukemia (Cancer and Leukemia Group B study 8364) . Blood . 1999;93:3931–3939
  29. Radich JP . Philadelphia chromosome-positive acute lymphocytic leukemia . Hematol Oncol Clin North Am . 2001;15:21–36
  30. Avivi I , Goldstone AH . Bone marrow transplant in Ph+ ALL patients . Bone Marrow Transplant . 2003;31:623–632
  31. Druker BJ , Sawyers CL , Kantarjian H , Resta DJ , Reese SF , Ford JM , et al.   Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome . N Engl J Med . 2001;344:1038–1042
  32. Ottmann OG , Druker BJ , Sawyers CL , Goldman JM , Reiffers J , Silver RT , et al.   A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias . Blood . 2002;100:1965–1971
  33. Wassmann B , Pfeifer H , Scheuring UJ , Binckebanck A , Gökbuget N , et al.   Early prediction of response in patients with relapsed or refractory Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL) treated with imatinib mesylate (Glivec) . Blood . 2004;103:1495–1498
  34. Thomas D , Faderl S , Cortes J , O′Brien S , Giles F , et al.   Update of the hyper-CVAD and imatinib mesylate regimen in Philadelphia (Ph) positive acute lymphocytic leukemia . Blood . 2004;104: (abstr 2738)
  35. Towatari M, Yanada M, Usui N, Takeuchi J, Sugiura I, Takeuchi M, et al  Combination of intensive chemotherapy and imatinib can rapidly induce high-quality complete remission for a majority of patients with newly diagnosed BCR-ABL-positive acute lymphoblastic . Blood . 2004;104:3507–3535
  36. Ottmann OG , Wassmann B , Pfeifer H , Gökbuget N , Bug G , et al.   Imatinib given concurrently with induction chemotherapy is superior to imatinib subsequent to induction and consolidation in newly diagnosed Philadelphia-positive acute lymphoblastic leukemia . Blood . 2004;104: (abstr 685)
  37. Pfeifer H , Wassmann B , Hoffmann WK , Komor M , Scheuring U , et al.   Risk and prognosis of central nervous system leukemia in patients with Philadelphia chromosome positive acute leukemias treated with imatinib mesylate (Glivec) . Clin Cancer Res . 2003;9:4674–4681
  38. Vignetti M , Fazi P , Meloni G , Chiarenza A , Malagola M , et al.   Dramatic improvement in CR rate and CR duration with imatinib in adult and elderly Ph+ ALL patients (Results of the GIMEMA prospective study LAL0201) . Blood . 2004;104: (abstr 2739)
  39. Ottmann OG , Wassmann B , Gökbuget N , Binckebanck A , Pfeifer H , Bruck R , et al.   A randomized phase II study comparing imatinib with chemotherapy as induction therapy in elderly patients with newly diagnosed Philadelphia-positive acute lymphoid leukemias . Hematology J . 2004;5(suppl):S112; (abstr)
  40. Thomas DA , Cortes J , Giles FJ , et al.   The modified hyper-CVAD regimen in newly diagnosed adult acute lymphoblastic leukemia . Blood . 2001;98(suppl 1):590a; (abstr 2474)
  41. Stock W , Yu D , Sanford B , Lozanski G , Cataland S , Vik R , et al.   Incorporation of alemtuzumab into front-line therapy of adult acute lymphoblastic leukemia is feasible (A phase I/II study from the Cancer and leukemia Group B (CALGB 10102)) . Blood . 2005;106(suppl 1):46a; (abstr 145)
  42. Faderl S , Gandhi V , Keating MJ , Jeha S , Plunkett W , Kantarjian HM . The role of clofarabine in hematologic and solid malignancies—Development of a next-generation nucleoside analog . Cancer . 2005;103:1985–1995
  43. Kurtzberg J , Ernst TJ , Keating MJ , et al.   Phase I study of 506U78 administered on a consecutive 5-day schedule in children and adults with refractory hematologic malignancies . J Clin Oncol . 2005;23:3396–3403
  44. Berg SL , Blaney SM , Devidas M , et al.   Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies (A report from the Children’s Oncology Group) . J Clin Oncol . 2005;23:3376–3382
  45. DeAngelo DJ , Yu D , Dodge RK , et al.   A phase II study of 2-amino-9-beta-D-arabinosyl-6-methoxy-9H-purine (506U78) in patients with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma (CALGB study 19801) . Blood . 2003;100(suppl 1):198a; (abstr 743)
  46. Isola L , Furman RR , Gandhi V , Thomas DA , Bennett JC , Banita S , et al.   Antileukemic activity and pharmacodynamics of intravenous forodesine (BCX-1777), a novel purine nucleoside phosphorylase (PNP) inhibitor, in phase I/II trials in patients with advanced T-cell malignancies . Blood . 2004;104: (abstr 4501)
  47. Gelmon KA , Tolcher A , Diab AR , et al.   Phase I study of liposomal vincristine . J Clin Oncol . 1999;17:697–705
  48. Thomas DA , Sarris A , O’Brien S , et al.   Phase II study of liposomal vincristine in relapsed or refractory adult acute lymphoblastic leukemia . Blood . 1999;94(suppl 1):238b; (abstr 4269)
  49. Offidani M , Corvatta L , Centurioni R , Leoni F , Malerba L , Mele A , et al.   High-dose daunorubicin as liposomal compound (Daunoxome) in elderly patients with acute lymphoblastic leukemia . Hematol J . 2003;4:47–53
  50. Thomas DA , Cortes J , Kantarjian HM . New agents in the treatment of acute lymphoblastic leukemia . Best Pract Res Clin Haematol . 2003;15:771–790

 Supported in part by grants from the National Institutes of Health CA-14599, CA-31946, CA-41287, and CA-33601.

PII: S0037-1963(06)00024-2

doi: 10.1053/j.seminhematol.2006.01.007

Seminars in Hematology
Volume 43, Issue 2 , Pages 126-133 , April 2006

Article Tools

* Image Usage & Resolution